Articles from Champions Oncology, Inc.

HACKENSACK, NJ / ACCESS Newswire / July 20, 2026 / Champions Oncology, Inc. (NASDAQ:CSBR), a global leader in clinically relevant oncology research models and translational solutions, will report its financial and operational results for the quarter and year ended April 30, 2026, on Monday, July 27, 2026, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. ET (1:30 P.M. PT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 347142. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 54320, or by accessing the investors section of the company's website within 72 hours.

Record Annual Revenue of $49.1 Million

HACKENSACK, NJ / ACCESSWIRE / July 14, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the fourth quarter ended April 30, 2022, on Thursday, July 21, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 908668. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 46134, or by accessing the investors section of the company's website within 72 hours.

HACKENSACK, NJ and TORONTO, ON / ACCESSWIRE / May 31, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, and Cyclica Inc. ("Cyclica"), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, announced today a therapeutic development partnership.

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

HACKENSACK, NJ / ACCESSWIRE / March 15, 2022 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for its third quarter of fiscal 2022, ended January 31, 2022. Third Quarter and Recent Highlights: - Record quarterly revenue of $13.2 million, an increase of 22% year over

HACKENSACK, NJ / ACCESSWIRE / March 11, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the third quarter ended January 31, 2022, on Tuesday, March 15, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30

HACKENSACK, NJ / ACCESSWIRE / February 15, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, announced today a co-development partnership with GigaMune. The partnership will combine Champions' novel Autologous Tumor Infiltrating Lymphocyte (TIL) platform with GigaMune's T Cell Receptor (TCR) Discovery

HACKENSACK, NJ / ACCESSWIRE / January 20, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, announced today a therapeutic co-development partnership with Fannin Innovation Studio. The partnership will combine novel therapeutic targets identified within Champions' Lumin platform with Fannin's Therapeutic

HACKENSACK, NJ / ACCESSWIRE / January 4, 2022 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative pharmacology, biomarker, and data platforms, announced today a therapeutic development partnership with Alloy Therapeutics. The partnership will combine novel therapeutic targets identified within Champions' Lumin platform with Alloy's fully-integrated in vivo

Reported income from operations of $263,000 HACKENSACK, NJ / ACCESSWIRE / December 13, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative pharmacology, biomarker, and data platforms, today announced its financial results for its second quarter of fiscal 2022, ended October 31, 2021. Second Quarter and Recent Highlights: - Record quarterly revenue of

HACKENSACK, NJ / ACCESSWIRE / December 6, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), leaders in transformative technology solutions utilized in oncology drug discovery and development will report its financial and operational results for the second quarter ended October 31, 2021, on Monday, December 13, 2021, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join

HACKENSACK, NJ / ACCESSWIRE / October 20, 2021 / Champions Oncology (NASDAQ:CSBR), a technology-enabled research organization announced the opening of a European laboratory located in the renowned OpenZone Life Sciences Campus in Bresso, Italy, on the doorstep of Milan. After launching preclinical and clinical GCLP-compliant biomarker services in 2019, Champions Oncology has rapidly grown to be a leader in the industry by providing scientific

HACKENSACK, NJ / ACCESSWIRE / September 13, 2021 / Champions Oncology, Inc. (Nasdaq:CSBR), leaders in transformative technology solutions utilized in drug discovery and development, today announced its financial results for its first quarter of fiscal 2022, ended July 31, 2021. First Quarter and Recent Highlights: - Record quarterly revenue of $11.3 million, an increase of 18% year over year - Reported non-GAAP income from operations,

HACKENSACK, NJ / ACCESSWIRE / September 2, 2021 / Champions Oncology, Inc. (CSBR), leaders in transformative technology solutionsutilized in oncology drug discovery and development will report its financial and operational results for the first quarter ended July 31, 2021, on Monday, September 13, 2021, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call

HACKENSACK, NJ / ACCESSWIRE / July 26, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider that is transforming drug discovery through innovative pharmacology, biomarker, and data platforms, announced today an expansion of its corporate strategy as they unveil their entry into the drug discovery and development space. Champions is organized as a dynamic ecosystem of business units centered around

Record Annual Revenue of $41 Million HACKENSACK, NJ / ACCESSWIRE / July 22, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), engaged in creating transformative technology solutions to be utilized in drug discovery and development, today announced its financial results for the year and fourth fiscal quarter ended April 30, 2021. Fourth Quarter and Fiscal Year 2021 Financial and Recent Business Highlights: - Record annual revenue of $41.0 million,

HACKENSACK, NJ / ACCESSWIRE / July 14, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider engaged in transforming drug discovery through innovative pharmacology, biomarker and data platforms, today announced it will report its financial and operational results for the fourth quarter ended April 30, 2021, on Thursday, July 22, 2021, before market open. The company will host a conference call to

HACKENSACK, NJ / ACCESSWIRE / June 15, 2021 / Champions Oncology (NASDAQ:CSBR), a technology-enabled research organization announced today that they have entered into a strategic partnership with BGI Americas. Through this partnership, BGI will now have access to Champions' Lumin Bioinformatics platform, a revolutionary data interpretation tool, to display and deliver proteomics data to their clients. By leveraging Lumin, BGI's customers will be